A Phase 2 interventional study of Psilocybin in Post Traumatic Stress Disorder, sponsored by COMPASS Pathways. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-13.
Sponsored by COMPASS Pathways · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing psilocybin in Stress Disorders, Post-Traumatic — 13 open to participants now, 16 under way, 3 of them phase 3. Psilocybin · Stress Disorders, Post-Traumatic.
Among the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic, this one is the 13th largest by enrollment, is one of 3 that started in 2022, is one of 10 in phase 2, and was the 4th registered.
2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 603 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →13 of the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic are open now, in 5 countries. Recruiting first, the newest first:
COMPASS Pathways · Sites in United States, Canada
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18–75
Sunstone Medical · Sites in United States
Ages 18+ · Women only
University of New Mexico · Sites in United States
Ages 18–89
Khyber Medical University Peshawar · Sites in Pakistan
Ages 18–60
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 11 · Phase 3 4
First in 2022; this study’s year is marked. 3 started in 2022.
This study's enrollment of 22 is below the median of 69 across 2,199 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 33 across the 20 interventional studies. Of the 3 that completed or were terminated, 2 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 20 have an industry lead sponsor. The 10 most frequent:
COMPASS Pathways is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
COMPASS Pathways has 2 studies filed under Stress Disorders, Post-Traumatic — fewer than ten, so there is no comparison to draw.
5 of the studies testing psilocybin in Stress Disorders, Post-Traumatic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07703722Phase 3Khyber Medical University PeshawarEffect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder | 2027-10-22 |
| NCT07737054Tel-Aviv Sourasky Medical CenterTrauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for PTSD | 2026-12-01 |
| NCT06888128Baylor College of MedicineState-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma | 2026-12-15 |
| NCT07506395University of New MexicoGroup Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder | 2027-05-01 |
| NCT06902974Sunstone MedicalPsilocybin-Assisted Therapy for Sexual Assault-Related PTSD | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Safety and Tolerability of COMP360 in Participants with Post-traumatic Stress Disorder
The Safety and Tolerability of COMP360 administered under supportive conditions in participants with Post-traumatic Stress Disorder
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
25 mg COMP360 Psilocybin
Drug: Psilocybin
Open label
Also known as: COMP360
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
A TEAE is defined as an adverse event (AE) that has an onset on or after the dose of study drug, or any pre-existing AE condition that has worsened on or after the dose of study drug.
Time frame: Up to 12 weeks
Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score From Baseline
CAPS-5 is a 30 item scale, each item is scored from 0-4, total severity score is calculated by taking the sum of the individual item scores (range: 0-80). Higher scores denote greater symptom severity.
Time frame: Week 12
Proportion of Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Responders
CAPS-5 is a 30 item scale, each item is scored from 0-4, total severity score is calculated by taking the sum of the individual item scores (range: 0-80). Higher scores denote greater symptom severity. A participant is defined as a responder if they have a greater than or equal to 15 point improvement on the CAPS-5 total severity score compared to Baseline.
Time frame: Week 12
Proportion of Clinician-Administered PTSD Scale From DSM-5 (CAPS-5) Remitters.
CAPS-5 is a 30 item scale, each item is scored from 0-4, total severity score is calculated by taking the sum of the individual item scores (range: 0-80). Higher scores denote greater symptom severity. A participant is defined as remitter at any post-baseline timepoint if their CAPS-5 total severity score is less than or equal to 20.
Time frame: Week 12
Change in Sheehan Disability Scale (SDS) Total Score From Baseline
SDS is a 5 item scale. The total score is calculated by summing the 3 domains (work/school, social life, and family life - each domain has a 0-10 range). The total score has a range from 0 to 30, with 0 representing no impairment and 30 representing severe impairment.
Time frame: Week 12
| Milestone | COMP360 Psilocybin |
|---|---|
| Started | 22 |
| Completed | 22 |
| Not completed | 0 |
A TEAE is defined as an adverse event (AE) that has an onset on or after the dose of study drug, or any pre-existing AE condition that has worsened on or after the dose of study drug.
| Participants | COMP360 Psilocybin |
|---|---|
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 22 |
CAPS-5 is a 30 item scale, each item is scored from 0-4, total severity score is calculated by taking the sum of the individual item scores (range: 0-80). Higher scores denote greater symptom severity.
| units on a scale | COMP360 Psilocybin |
|---|---|
| Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score From Baseline | -29.5 ± 15.43 |
CAPS-5 is a 30 item scale, each item is scored from 0-4, total severity score is calculated by taking the sum of the individual item scores (range: 0-80). Higher scores denote greater symptom severity. A participant is defined as a responder if they have a greater than or equal to 15 point improvement on the CAPS-5 total severity score compared to Baseline.
| Participants | COMP360 Psilocybin |
|---|---|
| Proportion of Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Responders | 17 |
CAPS-5 is a 30 item scale, each item is scored from 0-4, total severity score is calculated by taking the sum of the individual item scores (range: 0-80). Higher scores denote greater symptom severity. A participant is defined as remitter at any post-baseline timepoint if their CAPS-5 total severity score is less than or equal to 20.
| Participants | COMP360 Psilocybin |
|---|---|
| Proportion of Clinician-Administered PTSD Scale From DSM-5 (CAPS-5) Remitters. | 12 |
SDS is a 5 item scale. The total score is calculated by summing the 3 domains (work/school, social life, and family life - each domain has a 0-10 range). The total score has a range from 0 to 30, with 0 representing no impairment and 30 representing severe impairment.
| units on a scale | COMP360 Psilocybin |
|---|---|
| Change in Sheehan Disability Scale (SDS) Total Score From Baseline | -14.4 ± 8.21 |
Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| COMP360 Psilocybin | 0/22 (0%) | 0/22 (0%) | 22/22 (100%) |
| Event | COMP360 Psilocybin |
|---|---|
| NauseaGastrointestinal disorders | 8/22 |
| CryingGeneral disorders | 6/22 |
| FatigueGeneral disorders | 6/22 |
| Tension headacheNervous system disorders | 6/22 |
| HeadacheNervous system disorders | 6/22 |
| Hallucination, visualPsychiatric disorders | 5/22 |
| Visual impairmentEye disorders | 3/22 |
| Muscle tightnessMusculoskeletal and connective tissue disorders | 3/22 |
| ParaesthesiaNervous system disorders | 3/22 |
| ChillsGeneral disorders | 2/22 |
Safety Analysis Set - all participants who received study drug.
| Age, Categorical(Participants) | COMP360 Psilocybin |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 22 |
| >=65 years | 0 |
| Age, Continuous(years) | COMP360 Psilocybin |
|---|---|
| Mean | 39.0 ± 7.91 |
| Sex: Female, Male(Participants) | COMP360 Psilocybin |
|---|---|
| Female | 14 |
| Male | 8 |
| Ethnicity (NIH/OMB)(Participants) | COMP360 Psilocybin |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 22 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | COMP360 Psilocybin |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 4 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 18 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | COMP360 Psilocybin |
|---|---|
| United States | 9 |
| United Kingdom | 13 |
| CAPS-5 Total Symptom Severity Score(units on a scale) | COMP360 Psilocybin |
|---|---|
| Mean | 47.5 ± 9.78 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2022 to primary completion in Feb 2024, 20 months.
Results were first posted in Jun 2025, 1 year 4 months after primary completion.
Of 31 industry-sponsored phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 20 months is close to that.
Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Psilocybin
Stress Disorders, Post-Traumatic →
COMPASS Pathways